Hi @FeliBV !
Ah, Delee. I was a bit torn on this one myself.
Full disclosure up front, I did end up investing last March 2020.
It looks like you’ve already done some pretty solid research on them, so kudos to you.
I will say that bio/pharma isn’t an area I’m super experienced in, but I have made several investments in the space in companies that interest me, especially in the B2C HealthTech space. Anyway, in terms of things to look for, I always learn a LOT from reading the investor Q&A. There will be some much more experienced biotech investors who will ask some really insightful questions there, and you can learn a lot from them (as well as from how the founders respond).
Anyway, back to Delee – I haven’t looked in-depth at their most recent offering, but some of my overall notes from the first time I saw them were:
- One of my biggest concerns was around the amount of capital required to go to market and scale. As you know, anything that requires FDA approval can burn a lot of capital before (if ever) it gets a product that is approved. So I looked at this as more of a moonshot opportunity (very high risk and high chance of failure, but very high potential reward if it works out).
- On the plus side, I thought that there could be a huge potential demand for their product if successful, they had some solid backers (Y-Combinator and looks like StartX now), and for me, it was backing a meaningful company that could do some real good in the world in terms of cancer detection.
I know none of this is probably very helpful, but also don’t want to bias your (or others’) opinion of them too much.
Might also be worth taking a deep dive into how much they really accomplished with the funds raised since the last round. Have they made any meaningful progress, or are they burning capital and likely to require even more in another few months?
Cheers!
